Arsenal Biosciences (United States)

Recent papers from Arsenal Biosciences (United States)

1. Analysis of CA9 and PSMA expression in clear cell renal cell carcinoma (ccRCC) and the effect of prior therapies.Journal of Clinical Oncology · 2026
2. Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy2026
3. Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphomaLeukemia · 2025
4. Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeCancer Research · 2025
5. High resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discoveryeLife · 2025
6. High-resolution deep mutational scanning of the melanocortin-4 receptor enables target characterization for drug discoveryeLife · 2024
7. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignanciesBlood · 2024
8. Abstract 7034: Pooled CRISPR screening coupled with single-cell sequencing identifies modifiers of CAR T cell state in the context of chronic antigen stimulationCancer Research · 2024
9. Abstract 7042: Enhancing TCR T cell function in solid tumors through in vivo combinatorial screens and single-cell analysisCancer Research · 2024
10. Abstract 6319: Characterization of AB-1015 logic-gated CAR induction (ON kinetics), receptor turnover (OFF kinetics), and logic gate sensitivity to ALPG/P and MSLNCancer Research · 2024
11. Abstract 38: AB-2100, a PSMA-inducible CA9-specific CAR T cell product for the treatment of ccRCC provides long-term tumor responses in preclinical mouse modelCancer Research · 2024
12. Abstract B080: AB-1015, an Integrated Circuit T (ICT) cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancerCancer Research · 2024
13. Abstract B070: Logic-gated CAR T cell product AB-1015 response to ovarian cancer models with heterogeneous levels of ALPG/P antigenCancer Research · 2024
14. Degron-based bioPROTACs for controlling signaling in CAR T cells2024
15. Host Interactions with Engineered T-cell MicropharmaciesCancer Immunology Research · 2023
16. Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cellsCell Death and Disease · 2023
17. When Cancer Cells Become the Enablers of an Antitumor Immune ResponseCancer Discovery · 2022
18. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironmentJournal for ImmunoTherapy of Cancer · 2022
19. Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesCancers · 2020
20. Enteropathy-induced regulatory T cells inhibit intestinal CD4+ T cell responses against oral vaccines2020